Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer
Open Access
- 8 March 2011
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 128 (9), 2031-2037
- https://doi.org/10.1002/ijc.25559
Abstract
The receptor tyrosine kinase epidermal growth factor receptor (EGFR) is often expressed in solid malignant tumours, and the expression has been correlated to disease progression. Multiple new agents targeted against the EGFR have been developed during the last decade, but treatment selecting criteria are still not clear. This immunohistochemical study includes 386 colorectal cancer patients and focuses on EGFR expression variations within the tumour, comparing central parts to the invasive margin. Positive immunostaining for EGFR was evident in the central part in 176/386 (46%) of analyzed primary tumours. The invasive margin was positive in 222/386 (58%). A similar expression in both the central part and the invasive front was evident in 286/386 (74%). An increased score at the invasive margin compared to central parts (EGFRi) was evident in 97/386 (25%) of the tumours. Moreover, the results show a significant survival disadvantage for the EGFRi group, both in potentially curatively resected colon cancer patients (n = 170, p = 0.01) and in potentially curatively resected colon and rectal cancer patients combined (n = 273, p = 0.013). Multivariate survival analysis adjusted for age, gender, bowel localisation, grade, stage and tumour type showed an increased risk of cancer death for EGFRi tumours (HR, 1.53; 95% CI, 1.04–2.23; p = 0.029). A significant correlation between EGFR expression at the invasive margin and the presence of budding was seen (p = 0.0001). This investigation of a large patient material implies that EGFR immunohistochemical analysis still has a role in risk evaluation of colorectal cancer patients.This publication has 33 references indexed in Scilit:
- Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findingsEuropean Journal of Gastroenterology & Hepatology, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitionsClinical & Experimental Metastasis, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Epidermal growth factor receptor in colorectal carcinoma: correlation with clinico‐pathological prognostic factorsColorectal Disease, 2007
- Tumour budding at invasive margins and outcome in colorectal cancerColorectal Disease, 2007
- Tumor Budding as an Indicator of Isolated Tumor Cells in Lymph Nodes From Patients With Node-Negative Colorectal CancerDiseases of the Colon & Rectum, 2005
- Molecular mechanisms of invadopodium formationThe Journal of cell biology, 2005
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001